Abstract:Background Mitral regurgitation (MR) is a major contributor for heart failure (HF) and atrial fibrillation. Despite the advancement of MR surgeries, an effective medical therapy to mitigate MR progression is lacking. Sodium glucose cotransporter 2 inhibitors, a new class of antidiabetic drugs, has shown measurable benefits in reduction of HF hospitalization and cardiovascular mortality but the mechanism is unclear. We hypothesized that dapagliflozin (DAPA), a sodium glucose cotransporter 2 inhibitor, can improve cardiac hemodynamics in MR‐induced HF. Methods and Results Using a novel, mini‐invasive technique, we established a MR model in rats, in which MR induced left heart dilatation and functional decline. Half of the rats were randomized to be administered with DAPA at 10 mg/kg per day for 6 weeks. After evaluation of electrocardiography and echocardiography, hemodynamic studies were performed, followed by postmortem tissue analyses. Results showed that DAPA partially rescued MR‐induced impairment including partial restoration of left ventricular ejection fraction and end‐systolic pressure volume relationship. Despite no significant changes in electrocardiography at rest, rats treated with DAPA exhibited lower inducibility and decreased duration of pacing‐induced atrial fibrillation. DAPA also significantly attenuated cardiac fibrosis, cardiac expression of apoptosis, and endoplasmic reticulum stress‐associated proteins. Conclusions DAPA was able to suppress cardiac fibrosis and endoplasmic reticulum stress and improve hemodynamics in an MR‐induced HF rat model. The demonstrated DAPA effect on the heart and its association with key molecular contributors in eliciting its cardio‐protective function, provides a plausible point of DAPA as a potential strategy for MR‐induced HF. Nonstandard Abbreviations and Acronyms A atrial velocity DAPA dapagliflozin E transmitral early filling velocity ER endoplasmic reticulum MR mitral regurgitation Clinical Perspective What Is New? Using a novel and mini‐invasive rat model of mitral regurgitation, we demonstrated a cardio‐protective effect of dapagliflozin on cardiac remodeling. What Are the Clinical Implications? Our findings provide a plausible point of dapagliflozin as a potential strategy for mitral regurgitation‐induced heart failure. Mitral regurgitation (MR) is a valvular heart disease of high prevalence globally and is a known risk factor for atrial fibrillation (AF). 1 , 2 , 3 Although surgical interventions can arrest this pathophysiologic process to the extent of slowing down adverse cardiac remodeling, recurrence of regurgitation and AF correlates with a declining function of both left atrium (LA) and left ventricle (LV) and can lead to heart failure (HF). Given the importance of LA remodeling in disease progression, the cellular and molecular underpinnings of LA can be central to targeting a clinical therapy. Endoplasmic reticulum (ER) is a membrane system that is involved in protein folding, calcium homeostasis, and apoptosis. 4 There are 3 key signaling pathways including ATF6 (activating transcription factor 6), IRE1α (inositol‐requiring protein 1 alpha), and PERK (protein kinase RNA‐like endoplasmic reticulum kinase) that are induced by ER stress. 5 Under stress conditions such as oxidative stress, hypoxia, and calcium depletion, unfolded proteins aggregate and ER dysfunction esnsues. 6 Several reports indicated that ER stress‐associated apoptosis is a contributing factor for myocardial dysfunction and AF development. 6 , 7 , 8 Increased expression of ER stress mediator pro -Abstract Truncated-

Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling

Dapagliflozin reduces pulmonary vascular damage and susceptibility to atrial fibrillation in right heart disease

Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension

Dapagliflozin alleviates right heart failure by promoting collagen degradation by reducing ROS levels

Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating β-Hydroxybutyrate-activated Citrate Synthase

Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy

Dapagliflozin attenuates myocardial hypertrophy via activating the SIRT1/HIF-1α signaling pathway

Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF

Dapagliflozin: A sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling

Effects of Dapagliflozin in Combination with Hydrochlorothiazide on Cardiac Remodeling in Rats with Heart Failure After Myocardial Infarction

The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension

Dapagliflozin attenuates pressure overload-induced myocardial remodeling in mice via activating SIRT1 and inhibiting endoplasmic reticulum stress

Dapagliflozin attenuates the vulnerability to atrial fibrillation in rats with lipopolysaccharide-induced myocardial injury

Dapagliflozin Improves Cardiac Hemodynamics and Mitigates Arrhythmogenesis in Mitral Regurgitation-Induced Myocardial Dysfunction.

Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-β1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure

Dapagliflozin: a sodium–glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced cardiac fibrotic remodeling by regulating TGFβ1/Smad signaling

Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes

Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKα/TGF‐β/Smad signalling in type 2 diabetic rats

Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation

Dapagliflozin Ameliorates STZ-Induced Cardiac Hypertrophy in Type 2 Diabetic Rats by Inhibiting the Calpain-1 Expression and Nuclear Transfer of NF-κB